Facebook
Twitter
LinkedIn
ForwardWhat Do the BEST-CLI Results Mean for the Vascular Surgical Community?
CME credit is not offered for this activity.
This content is provided to members of SVS for free as a member benefit. If you are not a current member of SVS, click here for information on how to apply for membership.
Description
Recently, the results from the Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial were published in the New England Journal of Medicine. The research aimed to figure out the best treatment for patients with PAD associated with CLI. With the data being released, the trial has become a hot topic in the vascular surgery community. This recording of the April 12, 2023 SVS Presents... webcast dives into what the BEST-CLI results mean for vascular surgeons. Trial principal investigators, Alik Farber, MD and Matthew Menard, MD will present data, engage in a discussion with the esteemed panel.
Click the PROGRAM tab to see the program details.
Target Audience
All members of the vascular surgery field.
Price
SVS Member: Free
Non-Member: $35
SVS Disclaimer
The opinions or views expressed on the SVS OnDemand platform are those of the faculty and do not necessarily reflect the opinions, recommendations, or endorsement of SVS. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product or device mentioned. Information presented, as well as publications, technologies, products and/or services discussed, are intended to inform the learner about the knowledge, techniques, and experiences of SVS faculty who are willing to share such information with colleagues. The SVS disclaims any and all liability for damages to any individual user for all claims which may result from the use of said information, publications, technologies, products and/or services and events.
- BEST-CLI Trial Results – Matthew Menard, MD
- Trial Limitations & Points of Interpretation – Alik Farber, MD
- Panel Discussion and Questions
Moderators
Caitlin Hicks, MD
Vincent Rowe, MD
Speakers
Alik Farber, MD
Matthew Menard, MD
PanelistsTed Gifford, MD
Linda Harris, MD
Sharon Kiang, MD
Robert Molnar, MD
Andres Schanzer, MD
Peter Schneider, MD
Price
CME credit is not offered for this activity.
This content is provided to members of SVS for free as a member benefit. If you are not a current member of SVS, click here for information on how to apply for membership.
Description
Recently, the results from the Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial were published in the New England Journal of Medicine. The research aimed to figure out the best treatment for patients with PAD associated with CLI. With the data being released, the trial has become a hot topic in the vascular surgery community. This recording of the April 12, 2023 SVS Presents... webcast dives into what the BEST-CLI results mean for vascular surgeons. Trial principal investigators, Alik Farber, MD and Matthew Menard, MD will present data, engage in a discussion with the esteemed panel.
Click the PROGRAM tab to see the program details.
Target Audience
All members of the vascular surgery field.
Price
SVS Member: Free
Non-Member: $35
SVS Disclaimer
The opinions or views expressed on the SVS OnDemand platform are those of the faculty and do not necessarily reflect the opinions, recommendations, or endorsement of SVS. Participants should critically appraise the information presented and are encouraged to consult appropriate resources for information surrounding any product or device mentioned. Information presented, as well as publications, technologies, products and/or services discussed, are intended to inform the learner about the knowledge, techniques, and experiences of SVS faculty who are willing to share such information with colleagues. The SVS disclaims any and all liability for damages to any individual user for all claims which may result from the use of said information, publications, technologies, products and/or services and events.